Novel drug development opportunities for heparin

@article{Lever2002NovelDD,
  title={Novel drug development opportunities for heparin},
  author={Rebecca Lever and Clive P Page},
  journal={Nature Reviews Drug Discovery},
  year={2002},
  volume={1},
  pages={140-148}
}
The glycosaminoglycan heparin has been used in the clinic as an anticoagulant for more than 50 years. A fully characterized sequence in native heparin is known to be responsible for this activity. However, heparin is a complex polysaccharide, which has an array of properties that are unrelated to its anticoagulant activity. Recent research has provided us with an increased understanding of the specific structural requirements for the various actions of heparin, indicating that it might be… Expand
Non-anticoagulant effects of heparin: an overview.
TLDR
This chapter aims to provide an overview of the non-anticoagulant effects that have been ascribed to heparin, from those involving the binding and inhibition of specific mediators involved in the inflammatory process to effects in whole system models of disease. Expand
Synthesis of low-molecular-weight carbohydrate mimetics of heparin
Natural glycosaminoglycan heparin remains the most commonly prescribed anticoagulant for hospitalized patients in modern medical practice. Unfortunately, its administration can be accompanied by aExpand
Synthesis and Biological Activity of Anticoagulant Heparan Sulfate Glycopolymers
Heparin has been used as an anticoagulant drug for more than 70 years. The global distribution of contaminated heparin in 2007, which resulted in adverse clinical effects and over 100 deaths,Expand
Antimetastatic activities of heparins and modified heparins. Experimental evidence.
  • L. Borsig
  • Chemistry, Medicine
  • Thrombosis research
  • 2010
TLDR
This review summarizes the current experimental evidence on the biology of heparin as a potential treatment cancer progression and delineation of antimetastatic activity ofheparin is in the focus of several ongoing investigations. Expand
The Anticoagulant and Nonanticoagulant Properties of Heparin.
TLDR
This review focuses on the anticoagulant and nonanticoagULant activities of heparin and, where possible, discusses the underlying molecular mechanisms that explain the diversity ofheparin's biological actions. Expand
Heparin: An essential drug for modern medicine.
TLDR
Heparin is a life-saving drug, which belongs to few clinically used drugs without defined molecular structures in modern medicine, and has many pharmacological properties such as anti-inflammatory, anti-viral,Anti-angiogenesis, anti -neoplastic, and anti-metastatic effects though high affinity interactions with a variety of proteases, protease inhibitors, chemokines, cytokines, growth factors, and their respective receptors. Expand
Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.
TLDR
The present study focused on the structural characterization of N-acetylated gs-heparin Roneparstat, a promising anti-cancer heparanase-inhibiting drug currently being investigated in clinical trials. Expand
An efficient anticoagulant candidate: Characterization, synthesis and in vivo study of a fondaparinux analogue Rrt1.17.
TLDR
Nine analogues separated from commercially available crude fondaparinux sodium were identified, and their anticoagulant activity in vitro and vivo indicated that the well-defined derivative Rrt1.17 was a more efficient anticoaggulant candidate compared with fondAParinux. Expand
Heparin as an inhibitor of cancer progression.
  • L. Borsig
  • Medicine
  • Progress in molecular biology and translational science
  • 2010
TLDR
This chapter summarizes current experimental evidence on the biology of heparin during cancer progression, with the focus on potential mechanism ofheparin antimetastatic activity. Expand
Methods for the Production of Recombinant Heparosan, a Critical Heparin Precursor, from Nonpathogenic E. coli Strains.
TLDR
The methods for producing metabolically engineered size-specific heparin-like structures are outlined, by transforming the essential heparosan biosynthetic genes into nonpathogenic E.coli strain BL21(DE3), in a highly controlled manner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 133 REFERENCES
Synthesis of thrombin-inhibiting heparin mimetics without side effects
TLDR
The use of multistep converging synthesis to obtain sulphated oligosaccharides that meet the requirements of more potent and well-tolerated antithrombotic drugs is described. Expand
Heparin in inflammation: potential therapeutic applications beyond anticoagulation.
TLDR
In vivo data showing heparin's beneficial effects in various preclinical models of inflammatory disease as well as some clinical studies showing that the anti-inflammatory activities ofheparin may translate into therapeutic uses indicate that the anticoagulant activity can be distinguished from hepar in's anti- inflammatory properties. Expand
Heparin and cancer.
TLDR
The improved cancer outcome could not be attributed to prevention of VTE in any of the studies; therefore, it is reasonable to hypothesize that a beneficial effect of heparin may be mediated by mechanisms independent of anticoagulation. Expand
Low-molecular-weight heparin and cancer.
TLDR
Meta-analyses comparing unfractionated heparin (UFH) and low-molecular-weight heparIn (LMWH) for treatment of deep-vein thrombosis have shown apparent substantial improvement in cancer outcome in the subset of patients with malignancy who were randomly assigned to receive LMWH, providing a rationale for prospective clinical trials of LMWH in patients with cancer. Expand
Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung.
TLDR
Selectively O-desulfated heparin retains potent activity as an inhibitor of the cationic neutrophil proteases human leukocyte elastase and cathepsin G, both in vitro and in vivo, suggesting possible use of this new nonanticoagulant hepar in the treatment of a variety of lung disorders. Expand
Anticoagulant Action of Heparin
TLDR
It is proposed that heparin acts to accelerate inhibitor function by binding to antithrombin and inducing an allosteric modification in it, which renders the arginine in its reactive site more accessible to the serine in the active centre of thrombin4. Expand
Oligosaccharides corresponding to the regular sequence of heparin: chemical synthesis and interaction with FGF-2.
TLDR
The chemical synthesis of a tetra and a hexasaccharide, prepared as methyl glycosides, corresponding to the regular sequence of heparin are described, which inhibited the binding of FGF-2 on its receptor on human aorta vascular smooth muscle cells and inhibited the mitogenic effect of F GF-2. Expand
Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent
TLDR
NewHeparin derivatives were synthesized to enhance the oral absorption of heparin in the gastrointestinal tract to treat patients who are at a high risk of deep vein thrombosis or pulmonary embolism. Expand
Oral administration of low molecular weight heparin fractions in rabbits.
TLDR
New studies will be necessary if heparin and its fractions are to be provided with a satisfactory capacity to be absorbed, according to the molecular weights lower than 6000 D. Expand
Antithrombotic activity of oral unfractionated heparin.
TLDR
Oral heparin exhibits antithrombotic activity in a dose-dependent manner, with low levels in plasma, and Heparin could be demonstrated chemically in 52% of plasma samples and in 38% of aortic or vena caval endothelial samples. Expand
...
1
2
3
4
5
...